论文部分内容阅读
目的测定分化型甲状腺癌131I治疗时尿含量,间接推算体内滞留量,为临床诊断、防护,及医学规程的制定提供依据。方法分别收集病人24h和48h尿量,用加样器采样1ml,在甲功仪测定100s,并计数。按下列公式计算尿中131I含量,GBq(mCi)=标准源浓度/标准源计数/×(lml尿样计数/标准源的计数)×尿量(ml)。结果 40例131I治疗的甲癌病人,口服剂量不同,而24h、48h尿中131I排量基本相同,24h为82%,48h为94%,24h体内滞留量为18%,48h滞留量为10%。结论甲状腺癌131I治疗和甲亢131I治疗一样,是否可以在门诊治疗?甲癌131I尿中含量测定为远距离转移诊断提供参考。
Objective To determine the urinary content of 131I-treated thyroid cancer and to estimate the in vivo retention indirectly to provide the basis for clinical diagnosis, protection and medical procedure formulation. Methods The urine samples of patients were collected at 24h and 48h respectively, 1ml was sampled with a pipette, 100s were measured with a meridian, and counted. The urine 131I content was calculated according to the following formula, GBq (mCi) = standard source concentration / standard source count / x (lml urine sample / standard source count) x urine volume (ml). Results 40 cases of 131I-treated patients with carcinoma of the mouth, the oral dose is different, and 24h, 48h urine 131I displacement is basically the same, 24h 82%, 48h 94%, 24h retention in vivo 18%, 48h retention 10% . Conclusions 131I treatment of thyroid cancer is the same as that of 131I treatment of hyperthyroidism. Can it be treated in the outpatient department? The determination of 131I in the carcinoma of the thyroid cancer can provide a reference for the diagnosis of distant metastasis.